The effect of the chelating agent 4,7-bis（chlorosulfophenyl）-1,10-phenanthroline-2,9-dicarboxylic acid （BCPDA） labeled hepatitis B surface antibodies（HBsAb） on time-resolved fluoroimmunoassays（TRFIA） was inves...The effect of the chelating agent 4,7-bis（chlorosulfophenyl）-1,10-phenanthroline-2,9-dicarboxylic acid （BCPDA） labeled hepatitis B surface antibodies（HBsAb） on time-resolved fluoroimmunoassays（TRFIA） was investigated. The labeling detection method was established. The biotin-streptavidin（BAS） system was introduced, and the multi-stage amplification effect of the BAS system was analyzed. It is found that the BCPDA-Eu^3＋-HBsAb-BAS fluorescent marker can emit strong fluorescence. Compared to BCPDA-Eu^3＋-HBsAb, BCPDA-Eu^3＋-HBsAb-BAS demonstrates an enhanced fluorescence intensity by over 10 times. This study provides a guidance for the next generation non-radio immunoassays in clinical diagnosis,展开更多
基金Supported by the National Natural Science Foundation of China（No. 81572082） and the Natural Science Foundation of Jilin Province, China（Nos.2011713, 20150414015GH, 20150204010YY）.
文摘The effect of the chelating agent 4,7-bis（chlorosulfophenyl）-1,10-phenanthroline-2,9-dicarboxylic acid （BCPDA） labeled hepatitis B surface antibodies（HBsAb） on time-resolved fluoroimmunoassays（TRFIA） was investigated. The labeling detection method was established. The biotin-streptavidin（BAS） system was introduced, and the multi-stage amplification effect of the BAS system was analyzed. It is found that the BCPDA-Eu^3＋-HBsAb-BAS fluorescent marker can emit strong fluorescence. Compared to BCPDA-Eu^3＋-HBsAb, BCPDA-Eu^3＋-HBsAb-BAS demonstrates an enhanced fluorescence intensity by over 10 times. This study provides a guidance for the next generation non-radio immunoassays in clinical diagnosis,
